HDAC3 and gastric cancer: Furthermore, our in vivo and in vitro studies, which tracked gastric cancer cells in a mouse model of peritoneal carcinomatosis, demonstrates for the first time how Honokiol therapy, pharmacological inhibition, and gene silencing of HDAC3 effectively suppress the parietal peritoneum, thereby eliminating metastatic cancer cells.